Edinburgh BioQuarter has announced a collaborative partnership between the University of Edinburgh and Eli Lilly for novel cancer mechanisms.

The Edinburgh Cancer Discovery Unit (ECDU) will provide Lilly with access to the EDCU’s highly specialized biology models to potentially gain additional insight into the mechanism of action for select Lilly oncology compounds.

Neil Carragher, PI for the Edinburgh Cancer Research Center, said, “The collaboration with Lilly provides an excellent opportunity to partner the latest innovations in cancer research from the Edinburgh Cancer Discovery Unit with select compounds from Lilly’s oncology pipeline.”

Diane Harbison, head of business development at Edinburgh BioQuarter, said, “Edinburgh BioQuarter currently is involved in a number of collaborations. Following on from a partnership with Galapagos,  our recently announced collaboration with Biogen Idec and our longstanding association with GSK, this new strategic alliance further  demonstrates the industry’s growing awareness of the depth of world-class translational research being undertaken here in Edinburgh.”